Mitigation Strategies for US and EU Supply Chain Risk Introduced by the COVID-19 Pandemic

The current global health crisis has a profound effect on the pharmaceutical supply chain, from raw materials, to clinical supply, to store shelves. This 30-minute talk and Q&A will summarize the FDA and EMA recommendations and guidance regarding these challenges and provide Certara’s perspective on industry approaches.

Join us online May 27th at 11:15 am ET for a short talk, a few questions, in partnership with AAPS.

Button_Panelist.png

Title: Mitigation Strategies for US and EU Supply Chain Risk Introduced by the COVID-19 Pandemic
Date: Wednesday, May 27, 2020
Time: 11:15 AM EDT

Contributors

THUMB-James.png
James Zoshak, Associate Principal Regulatory Writer, Certara


THUMB_Terry.png
Terrance (Terry) Ocheltree, Ph.D., R.Ph., Vice President, Regulatory Strategy and CMC, Certara


THUMB_Renata.png
Renata Lavach-Savy, Associate Principal Regulatory Writer, Certara


THUMB_Rob.png
Robert Waterland, Ph.D., Associate Principal Regulatory Writer, Certara

Follow Us:

Additional text can go here...